Spyre Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell SYRE and other ETFs, options, and stocks.About SYRE
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency.
CEOCameron Turtle
CEOCameron Turtle
Employees65
Employees65
HeadquartersWaltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded2013
Founded2013
Employees65
Employees65
SYRE Key Statistics
Market cap2.56B
Market cap2.56B
Price-Earnings ratio-15.12
Price-Earnings ratio-15.12
Dividend yield—
Dividend yield—
Average volume942.62K
Average volume942.62K
High today$33.00
High today$33.00
Low today$32.30
Low today$32.30
Open price$32.87
Open price$32.87
Volume307.80K
Volume307.80K
52 Week high$35.31
52 Week high$35.31
52 Week low$10.91
52 Week low$10.91
Stock Snapshot
The current Spyre Therapeutics(SYRE) stock price is $32.94, with a market capitalization of 2.56B. The stock trades at a price-to-earnings (P/E) ratio of -15.12.
As of 2025-12-28, Spyre Therapeutics(SYRE) stock has fluctuated between $32.30 and $33.00. The current price stands at $32.94, placing the stock +2.0% above today's low and -0.2% off the high.
Spyre Therapeutics(SYRE) shares are trading with a volume of 307.8K, against a daily average of 942.62K.
In the last year, Spyre Therapeutics(SYRE) shares hit a 52-week high of $35.31 and a 52-week low of $10.91.
In the last year, Spyre Therapeutics(SYRE) shares hit a 52-week high of $35.31 and a 52-week low of $10.91.
Analyst ratings
100%
of 15 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own SYRE. This list is generated using Robinhood data, and it’s not a recommendation.